Why Did Kaleido Shares Plunge 10% On Tuesday?
- Kaleido Biosciences Inc (NASDAQ: KLDO) announced topline data from the non-IND/CTA clinical study evaluating KB295, a novel Microbiome Metabolic Therapy (MMT), in mild-to-moderate ulcerative colitis (UC).
- The study achieved the primary objective of safety and tolerability with no product-emergent serious adverse events reported.
- Subjects receiving KB295 experienced a reduction in three biomarkers, fecal calprotectin (FCP), fecal lactoferrin, and FimH, associated with UC disease activity was observed at the end of the study.
- These results are complemented by preclinical studies using human donor-derived microbiome communities.
- Total short-chain fatty acid (SCFA) production increased in ex-vivo studies to pharmacologically relevant levels to UC.
- The Company plans to initiate a phase 2 study with KB295 for mild-to-moderate UC patients in 1H of 2022.
- Price Action: KLDO stock closed 9.62% lower at $5.26 on Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Phase 2 TrialBiotech News Health Care Movers Trading Ideas General Best of Benzinga
